Unnamed Breast Cancer Program
Breast Cancer
Pilot/Phase 2Active
Key Facts
About Click Therapeutics
Click Therapeutics is redefining modern medicine by developing patient-centric digital treatments delivered via smartphone and prescribed by physicians. The company leverages a multimodal, platform-based approach that combines scientifically proven therapies with proprietary neuromodulatory mechanisms to drive clinically meaningful outcomes. With an FDA-cleared product for depression and multiple Phase 3 programs in neurology and psychiatry, Click is positioned at the forefront of the rapidly evolving digital therapeutics market. Their innovative Software-Enhanced Drugs™ platform represents a novel approach to enhancing traditional pharmacotherapy through digital interventions.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Verzenio (abemaciclib) | Eli Lilly | Approved |
| Pan-mutant-selective PI3Kα inhibitor | Novartis | Acquisition |
| Trodelvy | Royalty Pharma | Commercial |
| Trastuzumab biosimilar (IBI306) | Innovent Biologics | Phase 3 |
| Ogivri (trastuzumab biosimilar) | Viatris | Approved |
| Trastuzumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| Biosimilar Trastuzumab | Cipla | Commercial |
| Ogivri (Trastuzumab) | Biocon | Approved |
| Tamoxifen | Natco Pharma | Approved |
| ARV-027 | Arvinas | Phase 1 |
| Prognostic Genomic Tests | Eurobio Scientific | Commercial |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |